In some embodiments the present invention provides methods useful for the treatment of MMR-proficient and/or microsatellite stable (MSS) cancers and also useful for enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, and/or increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells. In some embodiments such methods involve administration of a combination of temozolomide and cisplatin, or a combination of temozolomide, cisplatin and an immune checkpoint inhibitor, to a subject in need thereof.

In some embodiments the present invention provides methods useful for the treatment of MMR-proficient and/or microsatellite stable (MSS) cancers and also useful for enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, and/or increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells. In some embodiments such methods involve administration of a combination of temozolomide and cisplatin, or a combination of temozolomide, cisplatin and an immune checkpoint inhibitor, to a subject in need thereof.

A method of treating glioma is provided. A combination protocol as described herein includes radiotherapy, chemotherapy, and pharmacotherapy. Resection of the glioma is optionally included in the combination protocol. Pharmacotherapy is conducted with an oleandrin-containing composition. Treatment of glioblastoma is particularly contemplated.

A method of treating glioma is provided. A combination protocol as described herein includes radiotherapy, chemotherapy, and pharmacotherapy. Resection of the glioma is optionally included in the combination protocol. Pharmacotherapy is conducted with an oleandrin-containing composition. Treatment of glioblastoma is particularly contemplated.

A method of treating glioma is provided. A combination protocol as described herein includes radiotherapy, chemotherapy, and pharmacotherapy. Resection of the glioma is optionally included in the combination protocol. Pharmacotherapy is conducted with an oleandrin-containing composition. Treatment of glioblastoma is particularly contemplated.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.